Citadel Advisors
IBER

Citadel Advisors’s Ibere Pharmaceuticals IBER Stock Holding History

Citadel Advisors’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-227,718
Closed -$2.26M – 15760
2022
Q3 		$2.26M Buy
227,718
+20
+0% +$197 ﹤0.01% 5359
2022
Q2 		$2.23M Sell
227,698
-550,000
-71% -$5.39M ﹤0.01% 5325
2022
Q1 		$7.63M Buy
777,698
+864
+0.1% +$8.42K ﹤0.01% 3403
2021
Q4 		$7.55M Sell
776,834
-5
-0% -$49 ﹤0.01% 3563
2021
Q3 		$7.53M Buy
776,839
+226,742
+41% +$2.19M ﹤0.01% 3556
2021
Q2 		$5.32M Buy
+550,097
New +$5.35M ﹤0.01% 4301

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Citadel Advisors's IBER Position: Q4 2022 in Review

Citadel Advisors sold out of Ibere Pharmaceuticals (IBER) in Q4 2022, closing a stake of 227,718 shares — an estimated $2.26M sold.

Citadel Advisors first reported a position in IBER in Q2 2021 and held it in 6 quarters. The position peaked at $7.63M in Q1 2022. 47 funds tracked by Wall St. Rank hold IBER as of Q4 2022.

  • Citadel Advisors reported no remaining Ibere Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 227,718 Ibere Pharmaceuticals shares in Q4 2022, an estimated $2.26M.
  • Citadel Advisors first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Citadel Advisors's Ibere Pharmaceuticals position peaked at $7.63M in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.